M J Forrest

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 426 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Active Cyclooxygenase-2 Inhibitor +10

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 397 citations · Full text

Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes

M J Forrest, S.-Y. Sun, Richard Hajdu et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 332 citations

Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

M J Forrest, Daniel M. Bloomfield, Richard J. Briscoe et al. · British Journal of Pharmacology · 2008 · 283 citations · Full text

Sialyl Lewisx-containing oligosaccharide attenuates myocardial reperfusion injury in cats.

Michael Buerke, Andrew S. Weyrich, Ze‐Yi Zheng et al. · Journal of Clinical Investigation · 1994 · 176 citations · Full text

Glycobiology, Cardiovascular Pharmacology, Pharmacotherapy +17